GLP-1 receptor agonists × cardiac & vascular function

TrialThe New England journal of medicine2024

Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.

Mikhail N Kosiborod et al.PubMed ↗Publisher ↗

What the trial testedrandomised · 616 people · 2024

Randomised comparison

Probably raised cardiac & vascular function

+7.30points+4.10 to +10.4

As reported

difference 7.3 points, 95% CI 4.10–10.4

Randomised comparison

Probably lowered body weight & composition

−6.40percentage points−7.60 to −5.20

As reported

difference −6.4 percentage points, 95% CI −7.60 to −5.20

Randomised comparison

Probably raised cardiac & vascular function

+0.67+0.55 to +0.80

As reported

difference 0.67, 95% CI 0.55–0.80

Three numbers in the abstract

the abstract, start to end

with placebo (estimated difference, 7.3 points; 95% confidence interval [CI], 4.1 to 10.4; P<0.001), and the mean percentage change in body weight was -9.8% with semaglutide and -3.4% with placebo (estimated difference, -6.4 percentage points; 95% CI, -7.6

treatment ratio for change in CRP level, 0.67 [95% CI, 0.55 to 0.80;

← favours treatmentfavours comparator →
could be chance
Cardiac & vascular function
7.34.10–10.4
Body weight & composition
−6.4−7.60 to −5.20
Cardiac & vascular function
0.670.55–0.80
GLP-1 receptor agonistsBody weight & compositionCardiac & vascular function

GLP-1 receptor agonists × cardiac & vascular functionhelps?mixed

unlikelylikely
0.500.50 without it

GLP-1 receptor agonists × body weight & compositionhelps?replicated

unlikelylikely
0.900.90 without it
← favours comparatorfavours treatment →
this papermore certainless certain
1 / 5

338 papers cite itlatest 60 shown

2024
2025
2026
this paperpooled ittrialcites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 38587233